🔴 Neumora Therapeutics is trading 6% down with no clear catalyst identified

Neumora Therapeutics is trading 5.95% down at $0.52, with no clear company-specific catalyst identified for October 2.

• The company’s investor-relations page lists August 14, 2026, as its latest press release.
• The Nasdaq is up 1.56% and the S&P 500 is up 0.99%, so broader market weakness does not explain the decline.
• Earlier navacaprant Phase 3 failures and the decision to discontinue the drug are prior context, not a confirmed catalyst for this session.